Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 13/20 | 0.62 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL5142066 | 0.99 | NPC1L1 (0.61) | NPC1L1BDKRB2CCR5OPRM1OPRD1 | |
| Water SCHEMBL5142065 | 0.99 | NPC1L1 (0.61) | NPC1L1BDKRB2CCR5OPRM1OPRD1 | |
| SCHEMBL8893726 | 0.90 | NPC1L1 (0.60) | NPC1L1BDKRB2CCR5OPRM1OPRD1 | |
| SCHEMBL10248371 | 0.89 | NPC1L1 (0.59) | NPC1L1BDKRB2CCR5OPRM1OPRD1 | |
| SCHEMBL318821 | 0.88 | NPC1L1 (0.57) | NPC1L1BDKRB2CCR5OPRM1OPRD1 | |
| SCHEMBL319341 | 0.87 | NPC1L1 (0.57) | NPC1L1BDKRB2CCR5OPRM1OPRD1 | |
| SCHEMBL5108734 | 0.87 | NPC1L1 (0.57) | NPC1L1BDKRB2CCR5OPRM1OPRD1 | |
| SCHEMBL1855447 | 0.87 | NPC1L1 (0.70) | NPC1L1BDKRB2OPRM1OPRK1DDR1 | |
| SCHEMBL8908168 | 0.86 | NPC1L1 (0.56) | NPC1L1BDKRB2CCR5OPRM1OPRD1 | |
| SCHEMBL5563023 | 0.86 | NPC1L1 (0.64) | NPC1L1BDKRB2CCR5OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287478-A1 | Nociceptin Analogues and Uses Thereof | ZEALAND PHARMA A/S (DK) | 2008-11-20 | — | — | US | disclosed |
| EP-1628978-A2 | TRIAZA-SPIRO COMPOUNDS AS NOCICEPTIN ANALOGUES AND USES THEREOF | Zealand Pharma A/S (DK) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004104004-A2 | TRIAZA-SPIRO COMPOUNDS AS NOCICEPTIN ANALOGUES AND USES THEREOF | ZEALAND PHARMA A/S (DK) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287478-A1 | Nociceptin Analogues and Uses Thereof | OPRL1, NPSR1, OPRK1 | NPC1L1 3684/4885BDKRB2 71/4885CCR5 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.